Table 1 –
Demographic and clinical characteristics among undetectable and detectable prostate-specific antigen (PSA) patients and overall cohort
| Variable | Undetectable PSA | Detectable PSA | p value |
|---|---|---|---|
| No. patients | 327 | 150 | |
| Patient age (yr) | 0. 3 | ||
| Median (Q1, Q3) | 60 (55, 64) | 61 (56, 65) | |
| Race, n (%) | <0.001a | ||
| African American | 46 (14) | 55 (37) | |
| Caucasian | 258 (79) | 92 (61) | |
| Other | 19 (5.8) | 3 (2.0) | |
| Unknown | 4 (1.2) | ||
| Pre-operative PSA (ng/ml) | <0.001a | ||
| Median (Q1, Q3) | 6.1 (4.6, 9) | 7.3 (5.1, 12) | |
| Unknown | 4 (2.7%) | ||
| RP grade groups, n (%) | <0.001a | ||
| Group 1 | 13 (4.0) | 19 (13) | |
| Group 2 | 161 (49) | 60 (40) | |
| Group 3 | 115 (35) | 41 (27) | |
| Group 4 | 16 (4.9) | 18 (12) | |
| Group 5 | 20 (6.1) | 12 (8.0) | |
| Unknown | 2 (0.61) | ||
| Extraprostatic extension, n (%) | 133 (41) | 86 (57) | <0.001a |
| Unknown | 2 (1.3) | ||
| Seminal vesicle invasion, n (%) | 50 (15) | 49 (33) | <0.001a |
| Unknown | 2 (0.61) | 1 (0.67) | |
| Lymph node invasion, n (%) | 36 (11) | 2 (1.3) | <0.001a |
| Unknown | 1 (0.31) | ||
| Positive surgical margins, n (%) | 110 (34) | 119 (79) | <0.001a |
| Pathological stage, n (%) | <0.001a | ||
| T2 | 182 (56) | 49 (33) | |
| T3a | 91 (28) | 44 (29) | |
| T3b | 50 (15) | 49 (33) | |
| T4 | 2 (0.61) | 6 (4.0) | |
| Unknown | 2 (0.61) | 2 (1.3) | |
| CAPRA-S risk, n (%) | <0.001a | ||
| Low | 109 (33) | 14 (9.3) | |
| Intermediate | 142 (43) | 61 (41) | |
| High | 55 (17) | 66 (44) | |
| Unknown | 21 (6.4) | 9 (6) | |
| Post-operative PSA (ng/ml) | <0.001a | ||
| Median (Q1, Q3) | — | 0.2 (0.1, 0.5) | |
| Time from RP to post-operative PSA (mo) | NA | ||
| Median (Q1, Q3) | 1.4 (1.4, 1.4) | 2.5 (1.8, 3.9) | |
| Follow-up time (mo) | NA | ||
| Median (Q1, Q3) | 45 (27, 73) | 77 (46, 126) | |
| RT before mets, n (%) | 109 (33) | 142 (95) | <0.001a |
| Unknown | 1 (0.67) | ||
| ADT before mets, n (%) | 23 (7.0) | 38 (25) | <0.001a |
| Unknown | 1 (0.31) | 1 (0.67) | |
| Decipher risk group, n (%) | 0.12 | ||
| Low | 142 (43) | 79 (53) | |
| Intermediate | 93 (28) | 40 (27) | |
| High | 92 (28) | 31 (21) |
ADT = androgen deprivation therapy; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical Score; mets = metastasis; RP = radical prostatectomy; RT = radiotherapy.
a
To compare patient characteristics among detectable PSA and undetectable patients, Wilcoxon rank sum test, and Fisher’s exact test were used for continuous and categorical variables, respectively.